Processing

Please wait...

Settings

Settings

Goto Application

1. WO2002036614 - PEPTIDES FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE

Publication Number WO/2002/036614
Publication Date 10.05.2002
International Application No. PCT/GB2001/004843
International Filing Date 01.11.2001
Chapter 2 Demand Filed 15.05.2002
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/47 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/4711
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
4701not used
4711Alzheimer's disease; Amyloid plaque core protein
Applicants
  • INSIGHT BIOTECHNOLOGY LIMITED [GB]/[GB] (AllExceptUS)
  • MILTON, Nathaniel, Gavin, Nicolas [GB]/[GB] (UsOnly)
Inventors
  • MILTON, Nathaniel, Gavin, Nicolas
Agents
  • GILL JENNINGS & EVERY
Priority Data
0026738.501.11.2000GB
0026739.301.11.2000GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PEPTIDES FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE
(FR) PEPTIDES DESTINES A UNE UTILISATION DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
Abstract
(EN)
Anti-sense peptides that correspond to Amyloid-ß protein residues 1-43 are identified, and are used to identify protein binding sites on enzymes that interact with Amyloid-ß. The anti-sense peptides can be used as, or to identify, therapeutic agents that prevent Amyloid-ß cytotoxicity, and may be useful in the treatment of Alzheimer's disease. The anti-sense peptides show sequence similarity to the protein kinase cdc2, and it has now been found that the cytotoxic form of Aß is phosphorylated.
(FR)
Selon l'invention, des peptides antisens correspondant à des résidus de protéine ß-amyloïde 1-43 sont identifiés, et employés pour l'identification de sites de liaison de protéines sur des enzymes interagissant avec ß-amyloïde. Ces peptides antisens peuvent servir d'agents thérapeutiques, ou à l'identification d'agents thérapeutiques empêchant la cytotoxicité de ß-amyloïde, et éventuellement se révéler utiles dans le traitement de la maladie d'Alzheimer. Lesdits peptides présentent une similarité séquentielle avec la protéine kinase cdc2, la forme cytotoxique de ßA étant phosphorylée.
Latest bibliographic data on file with the International Bureau